Navigation Links
Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A
Date:11/13/2013

DEERFIELD, Ill., Nov. 13, 2013 /PRNewswire/ -- Baxter International Inc. today announced it has completed enrollment in its Phase III clinical trial of BAX 855, an investigational extended half-life, recombinant factor VIII (rFVIII) treatment for hemophilia A. The ongoing trial is aimed at assessing the efficacy of the compound in reducing annualized bleed rates (ABR) in both prophylaxis and on-demand treatment schedules, and will also evaluate its safety and pharmacokinetic profile.

BAX 855 was designed based on the full-length ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] molecule, a product with 10 years of real-world experience. The BAX 855 molecule was modified with PEGylation technology designed to extend its duration of activity in the body.

"The BAX 855 development program is a priority for Baxter as we evaluate the potential to provide an efficacious and safe treatment with an extended half-life for patients with hemophilia," said Anders Ullman, M.D., Ph.D., vice president of global research and development in Baxter's BioScience business. "We are focused first and foremost on strategies to address optimal efficacy and minimize patients' bleeding episodes, while at the same time delivering on the convenience of less frequent dosing for this population with severe disease."

The Phase II/III multi-center, open-label study called PROLONG-ATE is evaluating BAX 855 among 146 adult patients with previously-treated severe hemophilia A. Patients participating in PROLONG-ATE receive treatment twice weekly (45 IU/kg) and are followed for six months. The primary endpoint of the study is the annualized bleed rate (ABR) during the treatment period.  The study is also evaluating the safety and immunogenicity of the compound when administered on either prophylaxis and on-demand treatment regimens. Other outcome measures include number of infusions needed t
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology news :

1. NSF report detailing growth in graduate enrollment in science & engineering in the past decade
2. King Richard III search in new phase after discovery has potential to rewrite history
3. National Geographic unveils new phase of genographic project
4. F1000Research, the first Open Science publisher, launches following a successful beta testing phase
5. In beef production, cow-calf phase contributes most greenhouse gases
6. FDA approves Phase II of stem cell trial for ALS led by U-Ms Dr. Eva Feldman
7. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
8. Carnegie Mellon neuroscientists discover new phase of synaptic development
9. Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
10. New sickle cell anemia therapy advances to Phase II clinical trials
11. Biozoom Enters Into Commercial Phase of Scanner Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... studies suggest that children delivered by Caesarean section have a ... it is still unknown why this is the case and ... Faculty of Health and Medical Sciences therefore decided to scrutinise ... system in a study of newborn mouse pups. ... section had developed a lower number of cells that strengthen ...
(Date:7/9/2014)... switch out one gene for another in a line ... fiction to reality within this decade. As with any ... of fixing disease-causing genes in humans, for example--as well ... put one of those concerns to rest: using gene-editing ... of mutations in the cells. The new results were ...
(Date:7/9/2014)... in Indiana state parks have helped restore the health ... overabundant populations of white-tailed deer, a Purdue study shows. ... professor of forest ecology, found that a 17-year-long Indiana ... state parks has successfully spurred the regrowth of native ... deer. , Jenkins said that while hunting may ...
Breaking Biology News(10 mins):Mouse study: Natural birth may strengthen the immune system 2No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Hunting gives deer-damaged forests in state parks a shot at recovery 2
... color, their knobby knees or their big feet to their children ... through those same genes. New research from the University of ... herpes virus 6 (HHV-6) to their children because it is integrated ... been shown to become part of the human DNA and then ...
... wolves chasing deer and other hoofed animals, new research ... to hunting. The study, published today in the open ... salmon is available, wolves will reduce deer hunting activity ... the University of Victoria and the Raincoast Conservation Foundation, ...
... permafrost in northern latitudes, which greatly increases microbial decomposition ... of warming in the region and could become a ... thus further warming, according to a new assessment in ... study, by Edward A. G. Schuur of the University ...
Cached Biology News:Virus weaves itself into the DNA transferred from parents to babies 2Wolves would rather eat salmon 2Thawing permafrost likely to boost global warming 2
(Date:1/15/2014)... (PRWEB) January 15, 2014 Cynvenio, a ... management through the genomic analysis of tumor cells in ... Finder™, a web-based cancer decision support application powered by ... with Cynvenio’s ClearID™ genomic test, Therapy Finder will provide ...
(Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... ... Terrosa Technologies, a provider of Cloud and SaaS migration ... wide sales, marketing and distribution responsibilities with Integrated Clinical Solutions ... Clinical Trial Management System (CTMS) tool for the pharmaceutical clinical ...
... , , , ... (OTC Bulletin Board: ADLS) announced that it received a complete ... (FDA) regarding its New Drug Application (NDA) for Restanza(TM) (cethromycin) ... pneumonia (CAP). In its letter, the FDA indicated that ...
... Novavax, Inc. (Nasdaq: NVAX ) today announced that it ... release to be issued after 8:00 a.m. Eastern Time on Friday, ... to discuss its financial results at 10:00 a.m. Eastern Time on ... President and Chief Executive Officer Dr. Rahul Singhvi and other members ...
Cached Biology Technology:Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 2Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 3Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia 2Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia 3Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia 4Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia 5
...
These 18x18 square No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick....
...
Experion spin filters are used to filter the gel matrix and gel stain solution prior to use with the Experion automated electrophoresis system. Supplied as 10 spin filters....
Biology Products: